Gilead Sciences, Inc. (GILD) stock price, chart and research
Gilead Sciences, Inc. (GILD) last traded at $167.58 at the close on November 16, 2026, down $0.50 (0.30%) on the day.
- Day range: $166.75 to $171.80
- 52-week range: $116.88 to $176.58
- Market cap: $207.86 billion
- Forward P/E: 16.51
- EPS (trailing 12 months): $-3.13
- Dividend yield: 1.96%
- Volume: 4,582,767 shares
About Gilead Sciences, Inc.
Sector: Healthcare; industry: Drug Manufacturers - General; headquarters: United States; CEO: Mr. Daniel Patrick O'Day; 17,000 employees; listed since 1992-01-22.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck &…
Financials
Revenue over the last 12 months was $30.99 billion, net income $-3.86 billion, a profit margin of -12.5%. Revenue grew 6.5% from a year earlier.
Institutional owners of GILD (13F)
Tracked managers holding GILD in 13F filings for the quarter ending 2026-09-30:
- Dimensional Fund Advisors LP: $1.16 billion, 0.21% of its portfolio (reduced)
- IMC-Chicago, LLC: $1.2 million, 0.01% of its portfolio (reduced)
ETFs that hold GILD
- SPY: SPDR S&P 500 ETF
- QQQ: Invesco QQQ Trust
- XLV: Health Care Select Sector SPDR
- VOO: Vanguard S&P 500 ETF
- IVV: iShares Core S&P 500 ETF
- QUAL: iShares MSCI USA Quality Factor ETF
- VTI: Vanguard Total Stock Market
- DYNF: iShares U.S. Equity Factor Rotation Active ETF
Research GILD with LunaTerminal
- Interactive chart from one day to ten years, with volume, technicals and comparisons.
- Valuation, analyst ratings, dividends, earnings history and recent news.
- Ask LunaTerminal about GILD: AI answers that cite dated data; no account needed for your first 300 credits
- 13F filings: which managers own what
- How advisors use LunaTerminal for market research
- What LunaTerminal does for financial advisors
Market data via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.